Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia

Immunotherapy has without question revolutionized the treatment of both hematologic and solid malignancies. Over the last several years novel strategies are being developed to incorporate these groundbreaking therapies into the care of patients with AML. Here we present an overview of the recent dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiatrowski, Kyle, Kim, Tae Hee, Przespolewski, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160191/
https://www.ncbi.nlm.nih.gov/pubmed/35664748
http://dx.doi.org/10.3389/fonc.2022.826768
Descripción
Sumario:Immunotherapy has without question revolutionized the treatment of both hematologic and solid malignancies. Over the last several years novel strategies are being developed to incorporate these groundbreaking therapies into the care of patients with AML. Here we present an overview of the recent developments in immunotherapy for AML with a focus on biomarkers of response. Topics reviewed include antibody drug conjugates, BiTEs, DARTs, checkpoint inhibitors, and cellular therapy as well as the development of biomarkers predictive of response in each class.

Ejemplares similares